Trial | NCT00109083  Report issue

Title

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    300
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
Study Started
Mar 31
2002
Primary Completion
Feb 28
2006
Study Completion
Feb 28
2006
Last Update
Aug 02
2012
Estimate

Drug RWJ-333369

Criteria 

Inclusion Criteria:

Established history of migraines for at least 1 year;
Have between 3 and 12 migraine attacks per month, and no more than 15 headache days in total per month;
Migraines must have first started before age 50.

Exclusion Criteria:

Most frequent headache type is not migraine;
Failed 3 or more studies of effective migraine-preventing medications;
Overuse of pain medications to treat migraines;
Not willing to stop use of migraine-preventing medications;
Significant serious concomitant diseases.
No Results Posted